DK1028729T3 - Fremgangsmåder til modulering af serin/threoninproteinkinasefunktion med 5-azaquinoxalinbaserede forbindelser - Google Patents

Fremgangsmåder til modulering af serin/threoninproteinkinasefunktion med 5-azaquinoxalinbaserede forbindelser

Info

Publication number
DK1028729T3
DK1028729T3 DK98948606T DK98948606T DK1028729T3 DK 1028729 T3 DK1028729 T3 DK 1028729T3 DK 98948606 T DK98948606 T DK 98948606T DK 98948606 T DK98948606 T DK 98948606T DK 1028729 T3 DK1028729 T3 DK 1028729T3
Authority
DK
Denmark
Prior art keywords
azaquinoxaline
methods
protein kinase
based compounds
threonine protein
Prior art date
Application number
DK98948606T
Other languages
Danish (da)
English (en)
Inventor
Gerald Mcmahon
Bernhard Kutscher
Eckhard Guenther
Harald App
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Application granted granted Critical
Publication of DK1028729T3 publication Critical patent/DK1028729T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK98948606T 1997-10-06 1998-10-05 Fremgangsmåder til modulering af serin/threoninproteinkinasefunktion med 5-azaquinoxalinbaserede forbindelser DK1028729T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6112397P 1997-10-06 1997-10-06

Publications (1)

Publication Number Publication Date
DK1028729T3 true DK1028729T3 (da) 2006-12-11

Family

ID=22033733

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98948606T DK1028729T3 (da) 1997-10-06 1998-10-05 Fremgangsmåder til modulering af serin/threoninproteinkinasefunktion med 5-azaquinoxalinbaserede forbindelser

Country Status (31)

Country Link
US (2) US6180631B1 (cs)
EP (1) EP1028729B1 (cs)
JP (1) JP2001518496A (cs)
KR (1) KR100633270B1 (cs)
CN (1) CN1169527C (cs)
AR (1) AR013542A1 (cs)
AT (1) ATE336250T1 (cs)
AU (1) AU757585B2 (cs)
BG (1) BG64969B1 (cs)
BR (1) BR9814814A (cs)
CA (1) CA2306257C (cs)
CY (1) CY1106223T1 (cs)
CZ (1) CZ298775B6 (cs)
DE (1) DE69835612T2 (cs)
DK (1) DK1028729T3 (cs)
ES (1) ES2268791T3 (cs)
HK (1) HK1031836A1 (cs)
HU (1) HUP0100302A3 (cs)
IL (2) IL135103A0 (cs)
MX (1) MXPA03011007A (cs)
NO (1) NO316598B1 (cs)
NZ (1) NZ503431A (cs)
PL (1) PL192039B1 (cs)
PT (1) PT1028729E (cs)
RU (1) RU2223753C2 (cs)
SK (1) SK4722000A3 (cs)
TR (2) TR200000906T2 (cs)
TW (1) TWI245765B (cs)
UA (1) UA71555C2 (cs)
WO (1) WO1999017759A2 (cs)
ZA (1) ZA988961B (cs)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (de) * 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
AU1053501A (en) * 1999-11-02 2001-05-14 Ajinomoto Co., Inc. Polyazanaphthalene compound and medicinal use thereof
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
AU2003209116A1 (en) * 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
WO2004027361A1 (en) * 2002-09-17 2004-04-01 University Of Virginia Patent Foundation Remote temperature sensing of small volume and related apparatus thereof
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
PT1636585E (pt) * 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
DE10323345A1 (de) 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
DE102004022383A1 (de) * 2004-05-06 2005-12-01 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen
EP1636228B1 (de) * 2003-05-23 2008-10-22 AEterna Zentaris GmbH Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
US20060293340A1 (en) * 2003-06-13 2006-12-28 Novartis Ag 2-Aminopyrimidine derivatives as raf kinase inhibitors
JP4777887B2 (ja) 2003-07-23 2011-09-21 バイエル、ファーマシューテイカルズ、コーポレイション 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素
CA2628039A1 (en) * 2005-11-11 2007-05-18 Aeterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
WO2010003308A1 (zh) * 2008-07-10 2010-01-14 卞化石 一氧化氮及其信息传递系统在制备恶性肿瘤靶向治疗药物中的应用
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2508184A1 (en) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
GB201118656D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
WO2014109414A1 (ja) * 2013-01-11 2014-07-17 富士フイルム株式会社 含窒素複素環化合物またはその塩
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
HUE053653T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR inhibitor és IGF1R inhibitor kombinációi
EP3848034A1 (en) 2014-03-26 2021-07-14 Astex Therapeutics Limited Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors
MY187540A (en) 2014-08-01 2021-09-28 Nuevolution As Compounds active towards bromodomains
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN108137546B (zh) 2015-09-23 2021-07-27 詹森药业有限公司 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途
CA2996857C (en) 2015-09-23 2024-05-21 Janssen Pharmaceutica Nv Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer
US12012394B2 (en) * 2018-02-19 2024-06-18 Washington University Alpha-synuclein ligands

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001017A (en) * 1972-12-05 1977-01-04 Ciba-Geigy Ag Process for the photopolymerization of ethylenically unsaturated compounds
US4043819A (en) * 1974-06-11 1977-08-23 Ciba-Geigy Ag Photo-polymerizable material for the preparation of stable polymeric images and process for making them by photopolymerization in a matrix
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3804990A1 (de) * 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
FR2656606B1 (fr) * 1989-12-28 1993-06-25 Roussel Uclaf Utilisation de derives du 9,10-dihydrophenanthrene pour la preparation d'un medicament anti-tumoral, application a titre de medicaments de derives du 9,10-dihydrophenanthrene et produits derives de cette structure.
WO1991015495A1 (en) 1990-04-02 1991-10-17 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
EP0586608A1 (en) 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
CA2140440A1 (en) 1992-08-06 1994-02-17 Ellen M. Dobrusin 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5723462A (en) * 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
GB9726851D0 (en) * 1997-12-19 1998-02-18 Zeneca Ltd Human signal transduction serine/threonine kinase

Also Published As

Publication number Publication date
DE69835612D1 (de) 2006-09-28
HUP0100302A2 (hu) 2001-06-28
CA2306257A1 (en) 1999-04-15
US6180631B1 (en) 2001-01-30
DE69835612T2 (de) 2007-08-16
CN1274284A (zh) 2000-11-22
BG104392A (en) 2000-12-29
PL339860A1 (en) 2001-01-15
EP1028729B1 (en) 2006-08-16
ES2268791T3 (es) 2007-03-16
BG64969B1 (bg) 2006-11-30
AR013542A1 (es) 2000-12-27
NO20001748L (no) 2000-04-05
HUP0100302A3 (en) 2006-03-28
CY1106223T1 (el) 2011-06-08
IL135103A0 (en) 2001-05-20
SK4722000A3 (en) 2002-06-04
AU757585B2 (en) 2003-02-27
MXPA03011007A (es) 2004-02-27
UA71555C2 (en) 2004-12-15
BR9814814A (pt) 2000-10-03
WO1999017759A3 (en) 2000-01-06
EP1028729A2 (en) 2000-08-23
JP2001518496A (ja) 2001-10-16
CZ20001129A3 (cs) 2000-10-11
AU9514198A (en) 1999-04-27
NO20001748D0 (no) 2000-04-05
NO316598B1 (no) 2004-03-01
US6727252B1 (en) 2004-04-27
ZA988961B (en) 1999-10-04
PL192039B1 (pl) 2006-08-31
CA2306257C (en) 2007-09-25
TWI245765B (en) 2005-12-21
ATE336250T1 (de) 2006-09-15
TR200100385T2 (tr) 2002-06-21
KR20010030934A (ko) 2001-04-16
CZ298775B6 (cs) 2008-01-23
PT1028729E (pt) 2006-12-29
RU2223753C2 (ru) 2004-02-20
KR100633270B1 (ko) 2006-10-16
NZ503431A (en) 2002-07-26
HK1031836A1 (en) 2001-06-29
WO1999017759A2 (en) 1999-04-15
CN1169527C (zh) 2004-10-06
TR200000906T2 (tr) 2000-11-21
IL135103A (en) 2007-06-17

Similar Documents

Publication Publication Date Title
DK1028729T3 (da) Fremgangsmåder til modulering af serin/threoninproteinkinasefunktion med 5-azaquinoxalinbaserede forbindelser
DK1017384T3 (da) Azabenzimidazolbaserede forbindelser til modulation af serin/threoninproteinkinasefunktion
CY2008013I1 (el) Αρυλσυμπυκωμενες αζαπολυκυκλικες ενωσεις
CY2008015I1 (el) Δικυκλικες ετepοαρωματικες ενωσεις σαν αναστολεις πρωτεϊνης κινασης τυροσινης
LTPA2014028I1 (lt) Pakeistieji 3-cianochinolinai kaip proteintirozinkinazės inhibitoriai
DK0996622T3 (da) Hidtil ukendte spiroazabicycliske, heterocykliske forbindelser
DK0912559T3 (da) Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
DK1036179T3 (da) Fremgangsmåde til fremstilling af polypeptider med egnet glucosilering
DK0812845T3 (da) Fremgangsmåde til fremstilling af sildenafil
NO990123D0 (no) Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer
NO990124D0 (no) Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer
DK0951467T3 (da) Substituerede nitrogenholdige heterocykliske forbindelser som inhibitorer af p38-proteinkinase
DK1005517T3 (da) Fremgangsmåde til fremstilling af diglycerider
IS5649A (is) Arýl sambrædd azapólýsýklísk efnasambönd
DK1028960T3 (da) Fremgangsmåde til fremstilling af thiazolidinedion
DK0970939T3 (da) Fremgangsmåde til fremstilling af methanol
DE69801549T2 (de) Schwalbenschwanzförmige Flüssigkristallverbindung
DK0946514T3 (da) Fremgangsmåde til fremstilling af n-substituerede 3-hydroxypyrazoler
DK1051401T3 (da) Fremgangsmåde til fremstilling af formylimidazoler
DK0949237T3 (da) Fremgangsmåde til fremstilling af dihydrocitral
ZA983669B (en) Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds.
DK0988263T3 (da) Fremgangsmåde til fremstilling af radioioderede neuroreceptormidler
DK0882035T3 (da) Fremgangsmåde til fremstilling af 2H-1-benzopyraner
DK1071674T3 (da) Fremgangsmåde til fremstilling af chlorbenzoxazoler
DK0959878T3 (da) Fremgangsmåde til behandling af nyresvigt